Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses topical pharmaceutical compositions with 5-alpha reductase inhibitors for treating androgenetic alopecia and reports no clinical results.

Anti-androgens are effective for female acne but less so for male-pattern hair loss, with side effects similar to birth control pills.

P-3074 effectively blocks scalp DHT better than oral finasteride.

This study found that the compound 9,11-dehydrocortexolone 17alpha-butyrate (CB-03-04) showed strong local antiandrogenic activity in animal models, suggesting potential for treating prostate conditions.

This study found that in hamster flank organs, 17βC inhibited enlargement caused by topical testosterone but not by DHT, suggesting potential use in androgen-related skin disorders like acne.

This study found that both topical and oral finasteride significantly reduced plasma DHT after one week, with lower finasteride plasma exposure for the topical formulation.

This study introduced a novel nonsteroidal androgen receptor antagonist that effectively controls sebum production in the golden Syrian hamster ear model through targeted follicular delivery.

This study reports that 4-(alkylthio)- and 4-(arylthio)-benzonitriles showed moderate sebum reduction as androgen receptor antagonists when applied topically in a validated animal model.

This case report found that a woman's hair loss, which progressed while using spironolactone and topical minoxidil, reversed after switching to flutamide therapy.

This article outlines the clinical features, evaluation, and treatment strategies for androgen excess in polycystic ovary syndrome, highlighting important diagnostic and management approaches but reporting no new research results.

This review highlights the challenges in screening for steroid 5 alpha-reductase inhibitors and discusses significant variability in the effectiveness of finasteride and dutasteride, calling for standardized testing methods to develop safer, more specific inhibitors from herbal preparations.

Male androgenetic alopecia involves hair follicle miniaturization due to DHT, with potential treatments using inhibitors and blockers.

The document concludes that treatments for female hair loss and excess body hair are available, but managing expectations is important.

Hair loss in androgenetic alopecia is caused by genetic factors and androgen excess, and can be treated with combined therapies.

This study found that testosterone replacement in castrated male rats counteracted endotoxemia-induced arterial baroreflex dysfunction without significantly affecting neuroinflammation.

Oral 5-alpha-reductase inhibitors for hair loss don't increase heart risk.

This review covers the pathogenesis, diagnosis, and potential new treatments for androgenetic alopecia but reports no new clinical findings, highlighting an ongoing need for effective therapies.

This review describes oncotherapy-induced alopecia in patients receiving hormone therapy for hormone-receptor-positive breast cancer and concludes that topical hormones should not be used due to oncogenic potential.

Mouse hair cells respond to male hormones by growing less, and this can be stopped by certain blockers.

This review discusses recent advancements in understanding the pathophysiology of androgenetic alopecia and highlights the potential for multilateral topical therapies to improve treatment efficacy with fewer side effects; it reports no new clinical results.

This review discusses current and emerging treatments for androgenetic alopecia, covering mechanisms, efficacy, and safety of both androgen-targeted and non-androgen-targeted approaches, but reports no new clinical results.

This review highlights that while finasteride and minoxidil effectively treat androgenetic alopecia, emerging options like dutasteride, mesotherapy, androgen blockers, and red LED therapy show promising results, especially when used in combination, though further research is needed for standardization and safety confirmation.

Androgens like testosterone affect skin health and can lead to conditions such as acne and hair loss, with various treatments available.

The conclusion is that small hair follicles cause baldness in macaques, and treatments like antiandrogens and minoxidil can prevent hair loss and promote regrowth.

This study synthesized and evaluated hydroxycinnamate derivatives for their ability to inhibit human SRD5A1, finding that three compounds showed significant inhibitory activity and low cytotoxicity. Compound 10a notably reduced SRD5A1 protein expression in cells, suggesting potential for nonsteroidal treatment of androgen-related conditions.

This study found that Arc/Arg3.1 expression in hippocampal neurons is regulated by sex steroids in a sex-dependent manner, with E2 increasing expression in females and DHT in males.

This review highlights various treatments for androgenetic alopecia that target its underlying pathophysiological mechanisms, reporting enhanced hair growth, especially when combining drugs, which shows improved outcomes over individual drug use alone.

In this study, the combination of finasteride and minoxidil significantly increased hair growth in balding male stumptail macaques compared to each drug alone.

This article discusses the complex interaction between androgens and the skin, highlighting elevated androgen levels in women with hirsutism, female-pattern hair loss, and acne, but reports no new clinical results.

This review discusses the potential of nanotechnology-based formulations for delivering topical minoxidil to improve hair loss treatment outcomes and reports no new clinical results, urging further research into their benefits and safety considerations.